Innovent Biologics valuation

1801 · HKEX · HKD

Compare Innovent Biologics
$85.80Change from previous close: +2.26%Absolute change: +$1.90

Close · November 17, 2026

Valuation

The P/E ratio is 111.5. The average price target of 28 analysts is $130.22.

Data as of November 16, 2026

Innovent Biologics compared with similar companies

Innovent Biologics's P/E (trailing 12 months): 111.5, +179% against the median of a group of 8 similar companies (40.0).

Innovent Biologics's metrics compared with similar companies
MetricInnovent BiologicsMedian25th–75th percentileBand
P/E (trailing 12 months)111.540.034.2 – 60.9High
Forward P/E33.632.027.9 – 49.3Middle
EV/EBITDA71.929.422.9 – 71.9Middle
Price/book6.046.043.07 – 9.42Middle
Price/sales9.4110.98.78 – 35.3Middle
Gross margin76.5%73.6%53.1% – 76.9%Middle
Operating margin7.4%21.1%10.7% – 32.0%Low
Net margin7.8%11.1%7.2% – 26.8%Middle
ROE7.0%10.4%5.0% – 16.3%Middle
Debt/equity0.110.150.07 – 0.38Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$147.79B
Enterprise value
$129.64B
PEG
0.75
EV/revenue
8.25

Profitability and growth

ROA
2.2%
ROIC
3.6%
Revenue growth (year over year)
44.8%
Earnings growth (year over year)
42.9%

Financial health

Total cash
$20B
Total debt
$2.32B
Current ratio
2.68
Quick ratio
2.35
Altman Z-Score
4.34
Piotroski F-Score
6.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
$130.22
Median price target
$128.72
High price target
$156.92
Low price target
$94.81
Analysts with a price target
28
Consensus
Strong buy
Forward EPS
$2.52
EPS estimate, current year
$1.41

Shares and trading

Beta
0.37
Average volume
11.71M
Shares outstanding
1.74B
Float
1.61B
Institutional ownership
58.7%
Insider ownership
6.2%